Abstract：【Objective】To investigate the clinical efficacy of letrozole combined with HCG in the treatment of patients with polycystic ovary syndrome. 【Methods】A total of 120 PCOS patients admitted to gynecology department of our hospital from January 2015 to August 2018 were selected and divided into observation group and control group according to random number table method, 60 cases in each group. The control group was treated with letrozole, while the observation group was treated with HCG on the basis of the control group. The levels of sex hormones testosterone (T), progesterone (PRGE), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2), vascular endothelial growth factor (VEGF), endostatin (ES) and the incidence of clinical efficacy and adverse reactions were compared between the two groups. 【Results】After treatment, the levels of T, FSH, LH, E2, VEGF and ES in the two groups were significantly decreased, but the levels of each index in the observation group were significantly lower than those in the control group (P<0.05); the ovarian volume in the observation group was significantly smaller than that in the control group, while the follicle diameter and the number of follicles in the observation group were significantly larger than those in the control group, the difference was statistically significant (P<0.05), but the endometrial thickness in the two groups was significantly different (P<0.05). There was no significant difference between the two groups (P>0.05). The ovulation rate and pregnancy rate in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Letrozole combined with HCG in the treatment of PCOS can effectively reduce the levels of sex hormones, vascular endothelial growth factor and ES, improve ovulation and pregnancy rate. It is safe and worthy of clinical application.
2019, Vol. 36 
